<DOC>
	<DOCNO>NCT01504334</DOCNO>
	<brief_summary>Idiopathic pulmonary fibrosis ( IPF ) chronic , progressive form lung disease characterize fibrosis support framework ( interstitium ) lung . By definition , term use cause pulmonary fibrosis unknown ( `` idiopathic '' ) . Microscopically , lung tissue patient show characteristic set histologic/pathologic feature know usual interstitial pneumonia ( UIP ) . UIP therefore pathologic counterpart IPF.Idiopathic pulmonary fibrosis characterize radiographically evident interstitial infiltrates predominantly affect lung base progressive dyspnea worsen pulmonary function . No therapy clearly show prolong survival . The current strict definition idiopathic pulmonary fibrosis provide new focus basic clinical research improve insight pathogenesis disorder stimulate development novel therapy . Pirfenidone proven antifibrotic anti-inflammatory property various vitro system animal model pulmonary fibrosis , although precise mechanism action remain unclear . It attenuate fibroblast proliferation , production fibrosis-associated protein cytokine , increase biosynthesis accumulation extracellular matrix response cytokine transform growth factor-β . It also show slow tumor cell proliferation inhibit fibroblast growth factor , epidermal growth factor platelet-derived growth factor . Pirfenidone widely approve clinical use China , study , safety efficacy evaluate see pirfenidone significant advantage placebo term improve lung function life quality etc . ( see primary secondary criterion ) slow deterioration lung function Chinese subject diagnose IPF .</brief_summary>
	<brief_title>Safety Efficacy Study Pirfenidone Treat Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . Written inform consent sign ; 2 . 1875 year age ; 3 . Clinically multidisciplinarily diagnose idiopathic pulmonary fibrosis ( see 2011 guidance ) ; 4 . Resting state PaO2≥50mg , FVC % ≥45 % normal predict value DLCO≥30 % normal predict value . 1 . Allergic pirfenidone ; 2 . Dyspnea symptom relieve past 6 month ; 3 . Patients acute exacerbation phase ; 4 . Diabetic patient whose fast venous glucose &gt; 11.1 mmol/L ; 5 . Patients malignant tumor hemorrhagic diseases ; 6 . Patients serious underlying pulmonary disease ; 7 . Patients serious heart disease ( NYHA class ⅢⅣ ) , liver disease ( ALT AST 2 time upper level normal value range ) , kidney disease ( Cr upper level normal value range ) ; 8 . Patients take Acetylcysteine past 3 month ; 9 . Patients take Prednisone &gt; 15mg/day ( equivalent amount glucocorticoid ) and/or Immunosuppresants past 3 month ; 10 . Patients take interferon , penicillamine , colchine agent treatment IPF ; 11 . Pregnant lactating woman ; 12 . Participated clinical trial past 1 month ; 13 . The investigator assess inappropriate participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>